Activation of Tim-3–Galectin-9 pathway improves survival of fully allogeneic skin grafts
- 30 April 2008
- journal article
- Published by Elsevier in Transplant Immunology
- Vol. 19 (1) , 12-19
- https://doi.org/10.1016/j.trim.2008.01.008
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- TIM-3 in autoimmunityCurrent Opinion in Immunology, 2006
- A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9Biochemical and Biophysical Research Communications, 2006
- Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisJournal of Clinical Investigation, 2006
- The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNature Immunology, 2005
- Galectin-9 as a Prognostic Factor with Antimetastatic Potential in Breast CancerClinical Cancer Research, 2005
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationThe Journal of Experimental Medicine, 2005
- Role of CD4+ and CD8+ T cells in murine skin and heart allograft rejection across different antigenic desparitiesTransplant Immunology, 2004
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002
- Apoptosis of T cells mediated by galectin-1Nature, 1995
- Galectins: A family of animal β-galactoside-binding lectinsPublished by Elsevier ,1994